Autopsy report · NCT05537766
Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies
Cause of deathFunding or business
“Sponsor decision to terminate study.”
Life of this trial
- Registered 2 months before it started.
- Ran for about 2 years 3 months before it stopped.
- 19 participants enrolled.
- Results were posted on the registry 1 year 1 month after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Kite, A Gilead Company
- Sponsor type
- Industry
- Conditions
- Relapsed/Refractory Waldenstrom Macroglobulinemia; Relapsed/Refractory Richter Transformation; Relapsed/Refractory Burkitt Lymphoma; Relapsed/Refractory Hairy Cell Leukemia
- Interventions
- Brexucabtagene Autoleucel; Cyclophosphamide; Fludarabine
- Participants
- 19
- Sites
- 26
- Countries
- Austria, France, Germany, Italy, Netherlands, Spain, Switzerland, United States
Trials that died the same way
- Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal Manifestations
“Sponsor decision to terminate the study” - Study of RP-6306 With FOLFIRI in Advanced Solid Tumors
“Sponsor decided to terminate the study” - A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer
“Sponsor decision to early terminate the study” - The REBALANCE Study - a Prospective, Multicenter, Randomized, Pivotal Study of the May Health System
“Business decision by sponsor to terminate the study” - Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation
“Study termination by the Sponsor”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.